Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | CASP1 | P29466 | 1/20 | 0.71 |
| ▸ | MYH9 | P35579 | 1/20 | 0.71 |
| ▸ | MYH10 | P35580 | 1/20 | 0.71 |
| ▸ | CASP7 | P55210 | 1/20 | 0.71 |
| ▸ | HBB | P68871 | 1/20 | 0.71 |
| ▸ | MYH2 | Q9UKX2 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23909233 | 1.00 | MAPT (0.71) | MAPTCYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL23909314 | 0.89 | MEN1 (0.57) | MAPTCYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL23909316 | 0.89 | MEN1 (0.57) | MAPTCYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL23235479 | 0.87 | MEN1 (0.57) | MAPTCYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL23235482 | 0.87 | MEN1 (0.57) | MAPTCYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL23235582 | 0.87 | MEN1 (0.54) | MAPTCYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL23909212 | 0.87 | MEN1 (0.54) | MAPTCYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL23909195 | 0.85 | MEN1 (0.54) | MAPTCYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL23909192 | 0.85 | MEN1 (0.54) | MAPTCYP3A4MEN1KMT2ACYP1A2 | |
| SCHEMBL23909198 | 0.83 | MEN1 (0.76) | MAPTCYP3A4MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIV OF FLORIDA RESEARCH FOUNDATION INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20210317117-A1 | NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | MYH2, MYO3B, MYO1B | MAPT 353/4885CYP3A4 1621/4885MEN1 1652/4885 |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | MYH2, MYO3B, MYO1B | MAPT 353/4885CYP3A4 1621/4885MEN1 1652/4885 |
| US-20210317117-A1 | NONMUSCLE MYOSIN II INHIBITORS FOR SUBSTANCE USE RELAPSE | MYH2, MYO3B, MYO1B | MAPT 441/4885CYP3A4 1705/4885MEN1 1418/4885 |
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | MYH2, MYO3B, MYO1B | MAPT 353/4885CYP3A4 1621/4885MEN1 1652/4885 |
| US-11649234-B2 | Nonmuscle myosin II inhibitors for substance use relapse | MYH2, MYO3B, MYO1B | MAPT 441/4885CYP3A4 1705/4885MEN1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.